Samar M Charabaty, MD
Rheumatology · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 5 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Community Hospital of the Monterey Peninsula · Hazel Hawkins Memorial Hospital · Salinas Valley Health Medical Center · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
20 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Charabaty’s office at (408) 848-2170 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A104924 · Current
Licensed to practise in California · since 2008 · expires 2028-06-30 · St Joseph'S University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Hazel Hawkins Memorial HospitalHollister, CACritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentNo overall ratingNo measure marked better or worse than the national rate
- Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Hazel Hawkins Memorial Hospital
Behind the star rating — Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.1) · 409 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 43 cases | No different | Jan 2024 – Dec 2024 |
See every measure and the patient survey for Salinas Valley Health Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.247 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.32 (0.34 to 2.3) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.42 (143.23 to 253.6) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 203 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 536 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,999 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.97 (1.83 to 6.1) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.87 to 3.76) · 1,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.78 (3.73 to 15.83) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (1.52 to 8.95) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 279 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.48 (0 to 1.11) · 6,011 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.487 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.082 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.373 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 491 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8 · 660 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 569 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 485 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.2 to 8.4) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,383 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$1,650,026
Medicare paid this office $1,650,026 for 434 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29 | $679,633 | None |
| Injection, denosumab, 1 mg | 107 | $221,248 | None |
| Injection, romosozumab-aqqg, 1 mg | 16 | $133,379 | None |
| Injection, golimumab, 1 mg, for intravenous use | 17 | $130,104 | None |
| Return visit (30+ min) | 380 | $94,383 | $107 |
See all 11 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29 | $679,633 | None |
| Injection, denosumab, 1 mg | 107 | $221,248 | None |
| Injection, romosozumab-aqqg, 1 mg | 16 | $133,379 | None |
| Injection, golimumab, 1 mg, for intravenous use | 17 | $130,104 | None |
| Return visit (30+ min) | 380 | $94,383 | $107 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 105 | $33,403 | $66 |
| New patient visit (60+ min) | 44 | $8,937 | $203 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $5,546 | $77 |
| New patient visit (45+ min) | 39 | $4,968 | $127 |
| Injection of drug or substance under skin or into muscle | 142 | $4,771 | $14 |
| Injection, zoledronic acid, 1 mg | 49 | $1,088 | None |
Who their Medicare patients are
434 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 10% · Women 84% · Also on Medicaid 11% · Health risk score 1.27. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Diabetes 28% · Coronary heart disease 27% · Depression 21% · Chronic kidney disease 20% · Heart failure 15% · COPD 14% · Cancer 13% · Atrial fibrillation 9% · Stroke 7% · Dementia 4%.
The office billed $3,296,954, Medicare allowed $2,095,838 and paid $1,650,026; for 109,839 services of 28 kinds; $1,489,205 of it was for drugs given in the office and $160,821 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 434 | 109,839 | 75 | 1.27 | $3,296,954 | $1,650,026 |
| 2023 | 419 | 107,428 | 75 | 1.14 | $3,366,480 | $1,647,389 |
| 2022 | 428 | 118,999 | 75 | 1.13 | $3,488,456 | $1,710,503 |
| 2021 | 427 | 112,929 | 75 | 1.18 | $3,950,199 | $2,124,386 |
| 2020 | 439 | 116,284 | 75 | 1.18 | $4,341,166 | $2,503,727 |
| 2019 | 514 | 133,130 | 73 | 1.15 | $4,204,520 | $2,371,450 |
| 2018 | 518 | 149,487 | 73 | 1.14 | $4,244,804 | $2,385,238 |
| 2017 | 512 | 134,737 | 73 | 1.23 | $3,947,697 | $2,100,537 |
| 2016 | 522 | 117,499 | 72 | 1.27 | $3,495,456 | $1,775,404 |
| 2015 | 587 | 71,338 | 73 | 1.20 | $2,651,152 | $1,229,103 |
| 2014 | 269 | 7,659 | 73 | 1.07 | $429,241 | $176,032 |
| 2013 | 23 | 27 | 66 | 1.19 | $561 | $189 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29 | $717,629 | None |
| Injection, denosumab, 1 mg | 103 | $205,074 | None |
| Injection, golimumab, 1 mg, for intravenous use | 16 | $143,404 | None |
| Return visit (30+ min) | 365 | $97,294 | $106 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 83 | $33,176 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $8,293 | $126 |
| New patient visit (45+ min) | 49 | $7,140 | $146 |
| New patient visit (60+ min) | 34 | $6,149 | $181 |
| Injection of drug or substance under skin or into muscle | 134 | $5,551 | $14 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,907 | $29 |
| Injection, zoledronic acid, 1 mg | 33 | $988 | None |
2022: 12 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 29 | $661,142 | None |
| Injection, golimumab, 1 mg, for intravenous use | 21 | $199,754 | None |
| Injection, denosumab, 1 mg | 113 | $195,053 | None |
| Return visit (30+ min) | 376 | $105,312 | $110 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 83 | $34,050 | $72 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $8,957 | $130 |
| New patient visit (45+ min) | 51 | $7,768 | $152 |
| Injection of drug or substance under skin or into muscle | 143 | $5,614 | $14 |
| New patient visit (60+ min) | 23 | $4,813 | $209 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,287 | $30 |
| Short return visit (20+ min) | 14 | $1,225 | $72 |
| Injection, zoledronic acid, 1 mg | 28 | $701 | None |
2021: 12 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 33 | $1,002,109 | None |
| Injection, golimumab, 1 mg, for intravenous use | 20 | $225,364 | None |
| Injection, denosumab, 1 mg | 120 | $201,827 | None |
| Return visit (30+ min) | 378 | $100,356 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 85 | $41,791 | $79 |
| New patient visit (45+ min) | 61 | $9,492 | $156 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $8,642 | $149 |
| Injection of drug or substance under skin or into muscle | 148 | $5,262 | $14 |
| Injection, zoledronic acid, 1 mg | 27 | $1,007 | None |
| Short return visit (20+ min) | 12 | $872 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $783 | $49 |
| Aspiration and/or injection of fluid from large joint | 11 | $750 | $58 |
2020: 15 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 37 | $1,364,068 | None |
| Injection, golimumab, 1 mg, for intravenous use | 23 | $255,380 | None |
| Injection, denosumab, 1 mg | 130 | $204,360 | None |
| Return visit (30+ min) | 378 | $81,532 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 84 | $45,657 | $76 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $7,583 | $152 |
| New patient visit (45+ min) | 53 | $7,083 | $134 |
| Injection of drug or substance under skin or into muscle | 155 | $4,742 | $14 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,083 | $32 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,514 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,460 | $73 |
| Short return visit (20+ min) | 22 | $1,406 | $56 |
| Dxa bone density measurement of hip, pelvis, spine | 23 | $1,186 | $52 |
| Injection, zoledronic acid, 1 mg | 19 | $672 | None |
| X-ray of spine, 1 view | 23 | $358 | $16 |
2019: 17 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 38 | $1,177,356 | None |
| Injection, golimumab, 1 mg, for intravenous use | 22 | $245,515 | None |
| Injection, denosumab, 1 mg | 138 | $210,947 | None |
| Injection, tocilizumab, 1 mg | 12 | $193,750 | None |
| Return visit (30+ min) | 410 | $105,990 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 84 | $45,352 | $76 |
| New patient visit (45+ min) | 59 | $8,606 | $146 |
| Administration of chemotherapy into vein, 1 hour or less | 12 | $8,102 | $147 |
| Injection of drug or substance under skin or into muscle | 162 | $6,003 | $17 |
| Dxa bone density measurement of hip, pelvis, spine | 107 | $5,597 | $52 |
| Short return visit (20+ min) | 43 | $3,065 | $65 |
| Administration of chemotherapy into vein, each additional hour | 12 | $2,482 | $30 |
| New patient visit (60+ min) | 13 | $2,386 | $184 |
| X-ray of spine, 1 view | 105 | $2,185 | $21 |
| Aspiration and/or injection of fluid from large joint | 23 | $2,177 | $54 |
| Injection, zoledronic acid, 1 mg | 17 | $750 | None |
| Infusion, normal saline solution, 250 cc | 12 | $24 | None |
2018: 16 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 40 | $1,049,888 | None |
| Injection, golimumab, 1 mg, for intravenous use | 20 | $250,617 | None |
| Injection, tocilizumab, 1 mg | 15 | $245,960 | None |
| Injection, denosumab, 1 mg | 151 | $212,744 | None |
| Return visit (30+ min) | 447 | $120,886 | $90 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $44,005 | $76 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $8,866 | $145 |
| New patient visit (60+ min) | 48 | $8,577 | $179 |
| Injection of drug or substance under skin or into muscle | 185 | $8,004 | $20 |
| Dxa bone density measurement of hip, pelvis, spine | 137 | $7,395 | $54 |
| Administration of chemotherapy into vein, each additional hour | 11 | $3,674 | $30 |
| New patient visit (45+ min) | 23 | $3,190 | $139 |
| X-ray of spine, 1 view | 136 | $2,682 | $20 |
| Aspiration and/or injection of fluid from large joint | 27 | $2,197 | $51 |
| Short return visit (20+ min) | 36 | $2,152 | $52 |
| Infusion, normal saline solution, 250 cc | 12 | $27 | None |
2017: 17 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 44 | $1,043,478 | None |
| Injection, tocilizumab, 1 mg | 13 | $231,450 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $199,294 | None |
| Injection, denosumab, 1 mg | 132 | $159,690 | None |
| Return visit (30+ min) | 441 | $140,340 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 78 | $40,320 | $71 |
| New patient visit (60+ min) | 62 | $10,753 | $173 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $10,687 | $141 |
| Injection of drug or substance under skin or into muscle | 165 | $8,012 | $25 |
| Dxa bone density measurement of hip, pelvis, spine | 138 | $7,257 | $53 |
| Short return visit (20+ min) | 60 | $6,990 | $68 |
| Administration of chemotherapy into vein, each additional hour | 15 | $4,333 | $28 |
| Aspiration and/or injection of fluid from large joint | 43 | $2,977 | $49 |
| X-ray of spine, 1 view | 134 | $2,753 | $21 |
| Injection, zoledronic acid, 1 mg | 12 | $581 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 14 | $79 | None |
| Infusion, normal saline solution, 250 cc | 18 | $30 | None |
2016: 18 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 35 | $711,806 | None |
| Injection, golimumab, 1 mg, for intravenous use | 15 | $239,212 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $220,705 | None |
| Injection, tocilizumab, 1 mg | 13 | $200,582 | None |
| Return visit (30+ min) | 461 | $156,661 | $90 |
| Injection, denosumab, 1 mg | 123 | $144,439 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $36,882 | $70 |
| New patient visit (60+ min) | 75 | $13,363 | $178 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $11,383 | $134 |
| Dxa bone density measurement of hip, pelvis, spine | 166 | $8,481 | $51 |
| Injection of drug or substance under skin or into muscle | 157 | $6,219 | $24 |
| Administration of chemotherapy into vein, each additional hour | 17 | $4,611 | $27 |
| X-ray of spine, 1 view | 166 | $3,151 | $19 |
| Aspiration and/or injection of fluid from large joint | 42 | $3,106 | $51 |
| Short return visit (20+ min) | 37 | $2,657 | $63 |
| Injection, zoledronic acid, 1 mg | 23 | $1,848 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 17 | $566 | None |
| Infusion, normal saline solution, 250 cc | 17 | $32 | None |
2015: 19 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 26 | $409,737 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 21 | $256,545 | None |
| Return visit (30+ min) | 493 | $143,651 | $92 |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $127,636 | None |
| Injection, denosumab, 1 mg | 86 | $94,226 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 95 | $27,264 | $71 |
| Administration of chemotherapy into vein, 1 hour or less | 21 | $15,395 | $137 |
| New patient visit (45+ min) | 70 | $9,995 | $143 |
| Dxa bone density measurement of hip, pelvis, spine | 181 | $9,490 | $52 |
| Administration of chemotherapy into vein, each additional hour | 21 | $6,217 | $28 |
| Injection, zoledronic acid, 1 mg | 44 | $6,016 | None |
| New patient visit (60+ min) | 27 | $5,136 | $190 |
| Injection of drug or substance under skin or into muscle | 109 | $4,246 | $25 |
| X-ray of spine, 1 view | 180 | $3,608 | $20 |
| Short return visit (20+ min) | 39 | $3,141 | $67 |
| Aspiration and/or injection of fluid from large joint | 36 | $2,817 | $53 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 15 | $918 | None |
| Injection into tendon or ligament | 11 | $752 | $50 |
| Infusion, normal saline solution, 250 cc | 21 | $34 | None |
2014: 13 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $49,301 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $41,964 | None |
| Return visit (30+ min) | 230 | $33,827 | $99 |
| New patient visit (45+ min) | 28 | $4,233 | $151 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 33 | $3,084 | $70 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $2,465 | $137 |
| Dxa bone density measurement of hip, pelvis, spine | 39 | $2,441 | $63 |
| Administration of chemotherapy into vein, each additional hour | 16 | $1,000 | $28 |
| X-ray of spine, 1 view | 38 | $885 | $23 |
| Aspiration and/or injection of fluid from large joint | 14 | $847 | $53 |
| Short return visit (20+ min) | 11 | $749 | $68 |
| Injection of drug or substance under skin or into muscle | 12 | $299 | $25 |
| Infusion, normal saline solution, 250 cc | 16 | $5 | None |
Drugs they prescribed that Part D paid
$2,568,149
Pharmacies billed $2,568,149 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (63 of 1,819) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%.
1,366 generic and 442 brand-name prescriptions · $2,568,149 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rinvoq | 67 | $444,887 | $6,640 |
| Enbrel Sureclick | 38 | $324,299 | $8,534 |
| Humira(Cf) | 37 | $284,021 | $7,676 |
| Xeljanz Xr | 45 | $261,996 | $5,822 |
| Enbrel | 17 | $215,483 | $12,675 |
See all 32 drugs
| Rinvoq | 67 | $444,887 | $6,640 |
| Enbrel Sureclick | 38 | $324,299 | $8,534 |
| Humira(Cf) | 37 | $284,021 | $7,676 |
| Xeljanz Xr | 45 | $261,996 | $5,822 |
| Enbrel | 17 | $215,483 | $12,675 |
| Orencia Clickject | 22 | $161,842 | $7,356 |
| Enbrel Mini | 17 | $122,066 | $7,180 |
| Prolia | 50 | $83,869 | $1,677 |
| Humira | 12 | $81,741 | $6,812 |
| Kineret | 12 | $66,490 | $5,541 |
| Benlysta | 11 | $29,211 | $2,656 |
| Tymlos | 11 | $28,864 | $2,624 |
| Methotrexate | 285 | $9,001 | $32 |
| Leflunomide | 80 | $6,826 | $85 |
| Hydroxychloroquine Sulfate | 171 | $6,361 | $37 |
| Mycophenolic Acid | 12 | $4,956 | $413 |
| Pilocarpine | 26 | $2,430 | $93 |
| Zoledronic Acid | 11 | $1,499 | $136 |
| Alendronate | 123 | $1,437 | $12 |
| Gabapentin | 71 | $1,207 | $17 |
| Celecoxib | 32 | $1,161 | $36 |
| Leucovorin | 25 | $1,154 | $46 |
| Prednisone | 148 | $1,095 | $7 |
| Duloxetine | 28 | $960 | $34 |
| Folic Acid | 69 | $835 | $12 |
| Cevimeline | 14 | $795 | $57 |
| Mycophenolate Mofetil | 13 | $721 | $55 |
| Sulfasalazine | 22 | $628 | $29 |
| Diclofenac | 18 | $413 | $23 |
| Tramadol | 63 | $305 | $5 |
| Allopurinol | 18 | $96 | $5 |
| Amlodipine Besylate | 18 | $68 | $4 |
Year by year
| 2024 | 1,819 | 295 | 4% (63) | 24% | $2,568,149 |
| 2023 | 1,773 | 291 | 4% (70) | 27% | $2,877,376 |
| 2022 | 1,833 | 287 | 4% (80) | 24% | $2,415,223 |
| 2021 | 1,769 | 284 | 6% (103) | 25% | $2,220,784 |
| 2020 | 1,901 | 299 | 6% (115) | 23% | $2,104,754 |
| 2019 | 2,130 | 292 | 6% (134) | 27% | $2,199,647 |
| 2018 | 2,123 | 313 | 8% (175) | 26% | $2,000,039 |
| 2017 | 2,319 | 312 | 7% (170) | 28% | $2,063,228 |
| 2016 | 2,516 | 338 | 7% (186) | 32% | $1,880,138 |
| 2015 | 2,355 | 391 | 9% (202) | 27% | $1,116,065 |
| 2014 | 3,537 | 321 | 4% (133) | 20% | $328,789 |
| 2013 | 5,837 | 289 | 4% (258) | 20% | $404,188 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Rinvoq | 72 | $581,212 | $8,072 |
| Humira(Cf) | 46 | $364,521 | $7,924 |
| Enbrel Sureclick | 40 | $324,770 | $8,119 |
| Orencia Clickject | 26 | $207,137 | $7,967 |
| Enbrel Mini | 23 | $202,151 | $8,789 |
| Xeljanz Xr | 30 | $192,427 | $6,414 |
| Prolia | 50 | $82,349 | $1,647 |
| Humira | 11 | $72,926 | $6,630 |
| Kineret | 13 | $67,318 | $5,178 |
| Actemra Actpen | 13 | $58,796 | $4,523 |
| Benlysta | 12 | $55,792 | $4,649 |
| Methotrexate | 280 | $13,328 | $48 |
| Leflunomide | 80 | $10,301 | $129 |
| Mycophenolic Acid | 16 | $8,531 | $533 |
| Hydroxychloroquine Sulfate | 139 | $7,624 | $55 |
| Savella | 16 | $7,449 | $466 |
| Cyclosporine Modified | 14 | $3,509 | $251 |
| Cevimeline | 20 | $3,488 | $174 |
| Mycophenolate Mofetil | 14 | $2,487 | $178 |
| Zoledronic Acid | 13 | $2,400 | $185 |
| Alendronate | 99 | $2,267 | $23 |
| Celecoxib | 29 | $2,079 | $72 |
| Prednisone | 160 | $1,988 | $12 |
| Gabapentin | 65 | $1,827 | $28 |
| Leucovorin | 31 | $1,757 | $57 |
| Duloxetine | 26 | $1,513 | $58 |
| Sulfasalazine | 38 | $1,101 | $29 |
| Pilocarpine | 13 | $1,029 | $79 |
| Diclofenac | 23 | $954 | $41 |
| Pregabalin | 15 | $446 | $30 |
| Tramadol | 70 | $387 | $6 |
| Allopurinol | 13 | $227 | $17 |
| Meloxicam | 19 | $225 | $12 |
| Folic Acid | 54 | $207 | $4 |
2022: 31 drugs
| Rinvoq | 66 | $469,775 | $7,118 |
| Humira(Cf) | 47 | $352,163 | $7,493 |
| Enbrel Sureclick | 38 | $289,317 | $7,614 |
| Orencia Clickject | 30 | $204,060 | $6,802 |
| Xeljanz Xr | 14 | $78,005 | $5,572 |
| Prolia | 48 | $72,795 | $1,517 |
| Actemra Actpen | 13 | $58,112 | $4,470 |
| Kineret | 12 | $57,537 | $4,795 |
| Benlysta | 13 | $50,569 | $3,890 |
| Olumiant | 14 | $37,412 | $2,672 |
| Methotrexate | 276 | $14,920 | $54 |
| Leflunomide | 92 | $13,930 | $151 |
| Hydroxychloroquine Sulfate | 156 | $12,802 | $82 |
| Celecoxib | 50 | $4,140 | $83 |
| Mycophenolate Mofetil | 20 | $3,480 | $174 |
| Cyclosporine Modified | 13 | $2,826 | $217 |
| Prednisone | 190 | $2,465 | $13 |
| Cevimeline | 19 | $2,364 | $124 |
| Gabapentin | 54 | $2,219 | $41 |
| Leucovorin | 34 | $1,906 | $56 |
| Alendronate | 98 | $1,680 | $17 |
| Sulfasalazine | 39 | $1,405 | $36 |
| Diclofenac | 28 | $1,164 | $42 |
| Pregabalin | 17 | $1,131 | $67 |
| Duloxetine | 16 | $939 | $59 |
| Tramadol | 78 | $616 | $8 |
| Modafinil | 12 | $412 | $34 |
| Folic Acid | 49 | $275 | $6 |
| Allopurinol | 19 | $274 | $14 |
| Methotrexate | 15 | $273 | $18 |
| Meloxicam | 13 | $64 | $5 |
2021: 29 drugs
| Rinvoq | 47 | $344,589 | $7,332 |
| Humira(Cf) | 44 | $312,671 | $7,106 |
| Enbrel Sureclick | 37 | $276,926 | $7,484 |
| Orencia Clickject | 25 | $127,325 | $5,093 |
| Enbrel | 14 | $87,798 | $6,271 |
| Orencia | 11 | $87,397 | $7,945 |
| Prolia | 60 | $83,505 | $1,392 |
| Xeljanz | 12 | $64,527 | $5,377 |
| Actemra Actpen | 13 | $55,314 | $4,255 |
| Kineret | 12 | $54,751 | $4,563 |
| Hydroxychloroquine Sulfate | 168 | $14,265 | $85 |
| Methotrexate | 249 | $12,949 | $52 |
| Leflunomide | 76 | $11,990 | $158 |
| Celecoxib | 55 | $3,250 | $59 |
| Cyclosporine Modified | 17 | $3,049 | $179 |
| Mycophenolate Mofetil | 13 | $2,901 | $223 |
| Prednisone | 199 | $2,867 | $14 |
| Pregabalin | 22 | $1,711 | $78 |
| Pilocarpine | 13 | $1,685 | $130 |
| Alendronate | 125 | $1,663 | $13 |
| Sulfasalazine Dr | 28 | $1,310 | $47 |
| Gabapentin | 42 | $1,294 | $31 |
| Diclofenac | 37 | $1,188 | $32 |
| Leucovorin | 16 | $1,097 | $69 |
| Duloxetine | 20 | $1,003 | $50 |
| Sulfasalazine | 15 | $903 | $60 |
| Tramadol | 94 | $524 | $6 |
| Allopurinol | 18 | $283 | $16 |
| Folic Acid | 38 | $190 | $5 |
2020: 33 drugs
| Enbrel Sureclick | 18 | $217,946 | $12,108 |
| Humira(Cf) | 28 | $201,487 | $7,196 |
| Enbrel | 27 | $177,109 | $6,560 |
| Enbrel Mini | 13 | $160,266 | $12,328 |
| Orencia | 23 | $158,814 | $6,905 |
| Xeljanz Xr | 17 | $137,862 | $8,110 |
| Orencia Clickject | 15 | $82,853 | $5,524 |
| Prolia | 53 | $68,167 | $1,286 |
| Kineret | 12 | $52,343 | $4,362 |
| Actemra Actpen | 11 | $46,798 | $4,254 |
| Hydroxychloroquine Sulfate | 203 | $19,434 | $96 |
| Methotrexate | 278 | $13,644 | $49 |
| Rasuvo | 12 | $11,301 | $942 |
| Leflunomide | 53 | $9,170 | $173 |
| Mycophenolate Mofetil | 19 | $4,831 | $254 |
| Colchicine | 11 | $4,080 | $371 |
| Prednisone | 196 | $2,509 | $13 |
| Pilocarpine | 12 | $2,503 | $209 |
| Pregabalin | 36 | $2,450 | $68 |
| Celecoxib | 48 | $2,129 | $44 |
| Cyclosporine Modified | 16 | $2,043 | $128 |
| Diclofenac | 55 | $2,031 | $37 |
| Sulfasalazine Dr | 35 | $1,821 | $52 |
| Alendronate | 150 | $1,696 | $11 |
| Duloxetine | 25 | $1,578 | $63 |
| Gabapentin | 52 | $1,000 | $19 |
| Leucovorin | 15 | $965 | $64 |
| Tramadol | 105 | $730 | $7 |
| Azathioprine | 12 | $703 | $59 |
| Sulfasalazine | 13 | $658 | $51 |
| Allopurinol | 19 | $335 | $18 |
| Amlodipine Besylate | 16 | $146 | $9 |
| Methylprednisolone | 12 | $122 | $10 |
2019: 39 drugs
| Enbrel Sureclick | 31 | $262,742 | $8,476 |
| Enbrel | 37 | $195,780 | $5,291 |
| Xeljanz Xr | 23 | $167,918 | $7,301 |
| Humira | 20 | $130,053 | $6,503 |
| Actemra | 36 | $124,523 | $3,459 |
| Enbrel Mini | 16 | $117,686 | $7,355 |
| Orencia | 15 | $101,769 | $6,785 |
| Xeljanz | 15 | $100,999 | $6,733 |
| Prolia | 51 | $62,263 | $1,221 |
| Orencia Clickject | 13 | $59,784 | $4,599 |
| Kineret | 13 | $53,800 | $4,138 |
| Tymlos | 21 | $37,960 | $1,808 |
| Lyrica | 34 | $24,471 | $720 |
| Hydroxychloroquine Sulfate | 196 | $22,770 | $116 |
| Leflunomide | 84 | $16,240 | $193 |
| Methotrexate | 278 | $15,532 | $56 |
| Pilocarpine | 15 | $3,735 | $249 |
| Cyclosporine Modified | 14 | $3,193 | $228 |
| Prednisone | 250 | $3,148 | $13 |
| Mycophenolate Mofetil | 19 | $2,975 | $157 |
| Gabapentin | 60 | $2,662 | $44 |
| Azathioprine | 27 | $2,420 | $90 |
| Celecoxib | 41 | $1,951 | $48 |
| Duloxetine | 23 | $1,810 | $79 |
| Diclofenac | 47 | $1,795 | $38 |
| Alendronate | 134 | $1,751 | $13 |
| Pregabalin | 13 | $1,537 | $118 |
| Leucovorin | 24 | $1,439 | $60 |
| Sulfasalazine Dr | 33 | $987 | $30 |
| Tramadol | 121 | $941 | $8 |
| Nifedipine Er | 11 | $839 | $76 |
| Sulfasalazine | 14 | $545 | $39 |
| Omeprazole | 17 | $375 | $22 |
| Allopurinol | 17 | $328 | $19 |
| Meloxicam | 31 | $293 | $9 |
| Amlodipine Besylate | 13 | $127 | $10 |
| Cyclobenzaprine | 14 | $117 | $8 |
| Acetaminophen-Codeine | 11 | $103 | $9 |
| Methotrexate | 15 | $102 | $7 |
2018: 36 drugs
| Enbrel Sureclick | 45 | $377,789 | $8,395 |
| Humira | 47 | $266,429 | $5,669 |
| Enbrel | 46 | $266,197 | $5,787 |
| Xeljanz Xr | 36 | $199,237 | $5,534 |
| Orencia | 20 | $117,729 | $5,886 |
| Xeljanz | 17 | $93,398 | $5,494 |
| Prolia | 47 | $55,123 | $1,173 |
| Kineret | 13 | $51,164 | $3,936 |
| Actemra | 12 | $49,748 | $4,146 |
| Forteo | 14 | $48,378 | $3,456 |
| Benlysta | 11 | $41,966 | $3,815 |
| Lyrica | 47 | $36,424 | $775 |
| Hydroxychloroquine Sulfate | 191 | $27,722 | $145 |
| Leflunomide | 93 | $25,387 | $273 |
| Methotrexate | 243 | $19,867 | $82 |
| Prednisone | 236 | $3,162 | $13 |
| Cyclosporine Modified | 15 | $3,078 | $205 |
| Diclofenac | 87 | $2,535 | $29 |
| Azathioprine | 21 | $2,509 | $119 |
| Gabapentin | 89 | $2,285 | $26 |
| Voltaren | 20 | $2,073 | $104 |
| Pilocarpine | 15 | $1,882 | $125 |
| Tramadol | 156 | $1,809 | $12 |
| Leucovorin | 25 | $1,727 | $69 |
| Alendronate | 101 | $1,233 | $12 |
| Amitriptyline | 20 | $769 | $38 |
| Nabumetone | 12 | $701 | $58 |
| Sulfasalazine | 15 | $634 | $42 |
| Duloxetine | 19 | $617 | $32 |
| Allopurinol | 27 | $476 | $18 |
| Omeprazole | 12 | $404 | $34 |
| Methotrexate | 25 | $339 | $14 |
| Methylprednisolone | 18 | $319 | $18 |
| Meloxicam | 28 | $255 | $9 |
| Acetaminophen-Codeine | 19 | $235 | $12 |
| Naproxen | 11 | $145 | $13 |
2017: 37 drugs
| Enbrel Sureclick | 78 | $487,543 | $6,251 |
| Enbrel | 54 | $277,581 | $5,140 |
| Humira | 24 | $184,449 | $7,685 |
| Forteo | 56 | $164,791 | $2,943 |
| Orencia | 39 | $159,399 | $4,087 |
| Humira | 13 | $141,787 | $10,907 |
| Xeljanz | 15 | $92,353 | $6,157 |
| Xeljanz Xr | 22 | $81,829 | $3,719 |
| Hydroxychloroquine Sulfate | 246 | $48,664 | $198 |
| Prolia | 43 | $47,076 | $1,095 |
| Lyrica | 49 | $39,681 | $810 |
| Leflunomide | 108 | $27,437 | $254 |
| Methotrexate | 245 | $25,533 | $104 |
| Cevimeline | 28 | $7,566 | $270 |
| Prednisone | 246 | $4,181 | $17 |
| Voltaren | 25 | $2,958 | $118 |
| Leucovorin | 39 | $2,678 | $69 |
| Mycophenolate Mofetil | 23 | $2,606 | $113 |
| Diclofenac | 88 | $2,543 | $29 |
| Gabapentin | 78 | $1,511 | $19 |
| Tramadol | 155 | $1,474 | $10 |
| Duloxetine | 44 | $1,443 | $33 |
| Celecoxib | 15 | $1,249 | $83 |
| Alendronate | 93 | $1,142 | $12 |
| Azathioprine | 12 | $1,128 | $94 |
| Sulfasalazine | 22 | $1,041 | $47 |
| Allopurinol | 39 | $726 | $19 |
| Nabumetone | 12 | $681 | $57 |
| Amitriptyline | 28 | $670 | $24 |
| Omeprazole | 19 | $430 | $23 |
| Methylprednisolone | 15 | $422 | $28 |
| Naproxen | 30 | $330 | $11 |
| Meloxicam | 23 | $217 | $9 |
| Cyclobenzaprine | 16 | $193 | $12 |
| Acetaminophen-Codeine | 13 | $150 | $12 |
| Sertraline | 11 | $109 | $10 |
| Amlodipine Besylate | 12 | $94 | $8 |
2016: 46 drugs
| Enbrel | 141 | $704,715 | $4,998 |
| Humira | 41 | $188,787 | $4,605 |
| Humira | 22 | $144,455 | $6,566 |
| Stelara | 11 | $138,854 | $12,623 |
| Orencia | 31 | $117,743 | $3,798 |
| Xeljanz | 28 | $107,291 | $3,832 |
| Forteo | 33 | $84,709 | $2,567 |
| Hydroxychloroquine Sulfate | 261 | $61,129 | $234 |
| Kineret | 13 | $48,237 | $3,711 |
| Xeljanz Xr | 11 | $38,762 | $3,524 |
| Prolia | 35 | $35,463 | $1,013 |
| Actemra | 17 | $29,941 | $1,761 |
| Lyrica | 42 | $28,040 | $668 |
| Leflunomide | 145 | $27,457 | $189 |
| Methotrexate | 253 | $19,888 | $79 |
| Cevimeline | 23 | $5,583 | $243 |
| Colchicine | 21 | $5,056 | $241 |
| Dexilant | 14 | $4,752 | $339 |
| Prednisone | 317 | $4,468 | $14 |
| Duloxetine | 48 | $4,028 | $84 |
| Voltaren | 34 | $3,537 | $104 |
| Pilocarpine | 14 | $2,773 | $198 |
| Celecoxib | 23 | $2,050 | $89 |
| Diclofenac | 42 | $1,858 | $44 |
| Leucovorin | 35 | $1,829 | $52 |
| Mycophenolate Mofetil | 30 | $1,489 | $50 |
| Tramadol | 145 | $1,439 | $10 |
| Cyclosporine Modified | 15 | $1,428 | $95 |
| Sulfasalazine | 38 | $1,382 | $36 |
| Alendronate | 116 | $1,257 | $11 |
| Azathioprine | 13 | $1,180 | $91 |
| Gabapentin | 69 | $932 | $14 |
| Amitriptyline | 28 | $765 | $27 |
| Omeprazole | 27 | $574 | $21 |
| Misoprostol | 12 | $530 | $44 |
| Hydrocodone-Acetaminophen | 29 | $465 | $16 |
| Methylprednisolone | 14 | $399 | $29 |
| Naproxen | 23 | $326 | $14 |
| Allopurinol | 12 | $203 | $17 |
| Acetaminophen-Codeine | 12 | $185 | $15 |
| Meloxicam | 23 | $149 | $6 |
| Amlodipine Besylate | 16 | $136 | $9 |
| Pantoprazole | 13 | $100 | $8 |
| Topiramate | 12 | $95 | $8 |
| Nabumetone | 12 | $92 | $8 |
| Cyclobenzaprine | 11 | $82 | $7 |
2015: 37 drugs
| Enbrel | 103 | $404,880 | $3,931 |
| Xeljanz | 55 | $159,156 | $2,894 |
| Orencia | 24 | $82,107 | $3,421 |
| Humira | 11 | $55,291 | $5,026 |
| Hydroxychloroquine Sulfate | 205 | $50,770 | $248 |
| Methotrexate | 237 | $25,005 | $106 |
| Lyrica | 48 | $19,036 | $397 |
| Prolia | 13 | $12,171 | $936 |
| Leflunomide | 92 | $11,519 | $125 |
| Cevimeline | 30 | $7,804 | $260 |
| Prednisone | 344 | $5,760 | $17 |
| Duloxetine | 46 | $4,842 | $105 |
| Voltaren | 53 | $4,159 | $78 |
| Colchicine | 16 | $3,603 | $225 |
| Pilocarpine | 19 | $3,220 | $169 |
| Celecoxib | 21 | $3,011 | $143 |
| Clobetasol Propionate | 12 | $2,209 | $184 |
| Tramadol | 147 | $1,491 | $10 |
| Alendronate | 133 | $1,267 | $10 |
| Leucovorin | 24 | $1,209 | $50 |
| Hydrocodone-Acetaminophen | 39 | $887 | $23 |
| Sulfasalazine | 31 | $882 | $28 |
| Mycophenolate Mofetil | 17 | $859 | $51 |
| Gabapentin | 53 | $750 | $14 |
| Omeprazole | 39 | $529 | $14 |
| Methotrexate | 14 | $419 | $30 |
| Insulin | 14 | $319 | $23 |
| Nabumetone | 11 | $308 | $28 |
| Amitriptyline | 15 | $275 | $18 |
| Acetaminophen-Codeine | 13 | $197 | $15 |
| Naproxen | 20 | $181 | $9 |
| Meloxicam | 25 | $166 | $7 |
| Simvastatin | 11 | $86 | $8 |
| Amlodipine Besylate | 14 | $85 | $6 |
| Lisinopril | 14 | $78 | $6 |
| Insulin | 11 | $73 | $7 |
| Trazodone | 11 | $62 | $6 |
2014: 63 drugs
| Enbrel | 19 | $53,284 | $2,804 |
| Januvia | 69 | $35,190 | $510 |
| Humalog | 48 | $25,677 | $535 |
| Humalog Mix 75-25 | 31 | $15,342 | $495 |
| Novolog Mix 70-30 | 25 | $11,833 | $473 |
| Advair Diskus | 27 | $10,291 | $381 |
| Novolog | 19 | $8,427 | $444 |
| Lantus Solostar | 21 | $6,658 | $317 |
| Lantus | 22 | $5,024 | $228 |
| Spiriva | 11 | $3,228 | $293 |
| Methotrexate | 37 | $2,889 | $78 |
| Metformin | 229 | $2,802 | $12 |
| Pravastatin | 80 | $2,471 | $31 |
| Atorvastatin | 86 | $2,394 | $28 |
| Omeprazole | 159 | $1,825 | $11 |
| Levothyroxine | 95 | $1,714 | $18 |
| Hydrocodone-Acetaminophen | 95 | $1,663 | $18 |
| Simvastatin | 152 | $1,302 | $9 |
| Lisinopril | 156 | $1,125 | $7 |
| Proair Hfa | 15 | $1,122 | $75 |
| Alendronate | 115 | $1,116 | $10 |
| Gabapentin | 59 | $1,078 | $18 |
| Oxybutynin Chloride Er | 20 | $1,071 | $54 |
| Bd Ultra-Fine Pen Needle | 30 | $1,048 | $35 |
| Losartan | 80 | $1,017 | $13 |
| Hydroxychloroquine Sulfate | 13 | $902 | $69 |
| Metoprolol | 25 | $891 | $36 |
| Amlodipine Besylate | 135 | $844 | $6 |
| Pioglitazone | 16 | $818 | $51 |
| Hydrochlorothiazide | 153 | $783 | $5 |
| Insulin | 36 | $783 | $22 |
| Tamsulosin | 32 | $705 | $22 |
| Carvedilol | 48 | $705 | $15 |
| Glipizide | 69 | $640 | $9 |
| Glimepiride | 44 | $601 | $14 |
| Polyethylene Glycol 3350 | 17 | $587 | $35 |
| Fluticasone Propionate | 28 | $578 | $21 |
| Clopidogrel | 35 | $573 | $16 |
| Escitalopram | 11 | $545 | $50 |
| Hydralazine | 11 | $535 | $49 |
| Metoprolol | 72 | $497 | $7 |
| Cyclobenzaprine | 26 | $429 | $16 |
| Prednisone | 39 | $417 | $11 |
| Digoxin | 13 | $398 | $31 |
| Enalapril Maleate | 24 | $381 | $16 |
| Insulin | 19 | $346 | $18 |
| Benazepril | 25 | $312 | $12 |
| Furosemide | 71 | $275 | $4 |
| Lisinopril-Hydrochlorothiazide | 37 | $238 | $6 |
| Fluoxetine | 21 | $211 | $10 |
| Famotidine | 30 | $203 | $7 |
| Propranolol | 31 | $201 | $6 |
| Spironolactone | 19 | $181 | $10 |
| Donepezil | 12 | $172 | $14 |
| Lactulose | 13 | $171 | $13 |
| Ranitidine | 18 | $159 | $9 |
| Terazosin | 17 | $152 | $9 |
| Trazodone | 27 | $145 | $5 |
| Tramadol | 29 | $143 | $5 |
| Pantoprazole | 11 | $131 | $12 |
| Citalopram Hbr | 17 | $128 | $8 |
| Lovastatin | 12 | $93 | $8 |
| Atenolol | 16 | $86 | $5 |
2013: 102 drugs
| Januvia | 126 | $54,538 | $433 |
| Humira | 13 | $30,963 | $2,382 |
| Novolog Mix 70-30 | 48 | $20,225 | $421 |
| Humalog Mix 75-25 | 61 | $17,491 | $287 |
| Humalog | 44 | $17,047 | $387 |
| Lantus Solostar | 57 | $14,717 | $258 |
| Lantus | 74 | $14,705 | $199 |
| Cymbalta | 25 | $10,569 | $423 |
| Crestor | 25 | $8,133 | $325 |
| Novolog | 28 | $7,353 | $263 |
| Advair Diskus | 17 | $7,148 | $420 |
| Clonidine | 27 | $6,184 | $229 |
| Spiriva | 14 | $5,958 | $426 |
| Novolog Mix 70-30 Flexpen | 20 | $5,873 | $294 |
| Metformin | 354 | $5,251 | $15 |
| Diovan | 12 | $4,510 | $376 |
| Atorvastatin | 115 | $4,486 | $39 |
| Nexium | 13 | $4,003 | $308 |
| Omeprazole | 239 | $3,646 | $15 |
| Simvastatin | 314 | $3,574 | $11 |
| Gabapentin | 133 | $3,546 | $27 |
| Lovaza | 21 | $3,362 | $160 |
| Clopidogrel | 66 | $3,077 | $47 |
| Lyrica | 14 | $2,998 | $214 |
| Pravastatin | 128 | $2,984 | $23 |
| Tradjenta | 11 | $2,804 | $255 |
| Symbicort | 11 | $2,622 | $238 |
| Hydrocodone-Acetaminophen | 181 | $2,618 | $14 |
| Methotrexate | 37 | $2,591 | $70 |
| Lisinopril | 258 | $2,241 | $9 |
| Dexilant | 14 | $2,206 | $158 |
| Pioglitazone | 22 | $2,136 | $97 |
| Escitalopram | 23 | $2,085 | $91 |
| Amlodipine Besylate | 231 | $2,021 | $9 |
| Tamsulosin | 63 | $2,011 | $32 |
| Losartan | 131 | $1,857 | $14 |
| Levothyroxine | 148 | $1,823 | $12 |
| Proair Hfa | 33 | $1,652 | $50 |
| Hydralazine | 45 | $1,622 | $36 |
| Carvedilol | 102 | $1,611 | $16 |
| Bd Ultra-Fine Pen Needle | 46 | $1,535 | $33 |
| Alendronate | 130 | $1,426 | $11 |
| Fluticasone Propionate | 56 | $1,394 | $25 |
| Isosorbide Dinitrate | 15 | $1,356 | $90 |
| Lansoprazole | 18 | $1,355 | $75 |
| Insulin | 60 | $1,346 | $22 |
| Montelukast | 18 | $1,260 | $70 |
| Fenofibrate | 26 | $1,161 | $45 |
| Hydrochlorothiazide | 195 | $1,135 | $6 |
| Mycophenolate Mofetil | 11 | $1,080 | $98 |
| Glimepiride | 66 | $992 | $15 |
| Polyethylene Glycol 3350 | 27 | $978 | $36 |
| Metoprolol | 27 | $956 | $35 |
| Metoprolol | 117 | $952 | $8 |
| Levetiracetam | 12 | $772 | $64 |
| Glipizide | 67 | $685 | $10 |
| Lisinopril-Hydrochlorothiazide | 50 | $673 | $13 |
| Oxybutynin Chloride Er | 14 | $671 | $48 |
| Furosemide | 127 | $658 | $5 |
| Benazepril | 67 | $621 | $9 |
| Famotidine | 64 | $596 | $9 |
| Phenytoin | 17 | $567 | $33 |
| Fluoxetine | 34 | $548 | $16 |
| Econazole Nitrate | 16 | $540 | $34 |
| Donepezil | 27 | $517 | $19 |
| Enalapril Maleate | 47 | $516 | $11 |
| Ventolin Hfa | 12 | $510 | $42 |
| Voltaren | 12 | $467 | $39 |
| Sumatriptan | 12 | $455 | $38 |
| Cyclobenzaprine | 39 | $403 | $10 |
| Spironolactone | 20 | $393 | $20 |
| Insulin | 17 | $381 | $22 |
| Ramipril | 24 | $361 | $15 |
| Trazodone | 64 | $349 | $5 |
| Tramadol | 47 | $345 | $7 |
| Prednisone | 49 | $339 | $7 |
| Pantoprazole | 26 | $327 | $13 |
| Diltiazem 24hr Er | 11 | $327 | $30 |
| Terazosin | 32 | $326 | $10 |
| Insulin | 12 | $305 | $25 |
| Digox | 19 | $278 | $15 |
| Azithromycin | 20 | $272 | $14 |
| Diltiazem 24hr Cd | 11 | $247 | $22 |
| Ranitidine | 25 | $244 | $10 |
| Unifine Pentips | 13 | $230 | $18 |
| Citalopram Hbr | 33 | $225 | $7 |
| Hydroxyzine | 13 | $191 | $15 |
| Isosorbide Mononitrate Er | 13 | $184 | $14 |
| Acetaminophen-Codeine | 17 | $183 | $11 |
| Propranolol | 27 | $182 | $7 |
| Lactulose | 12 | $181 | $15 |
| Atenolol | 24 | $176 | $7 |
| Nitrostat | 13 | $147 | $11 |
| Triamcinolone Acetonide | 15 | $141 | $9 |
| Paroxetine | 12 | $129 | $11 |
| Methimazole | 12 | $99 | $8 |
| Amiodarone | 13 | $89 | $7 |
| Ropinirole | 11 | $82 | $7 |
| Zolpidem | 17 | $77 | $5 |
| Sulfamethoxazole-Trimethoprim | 11 | $69 | $6 |
| Amitriptyline | 11 | $64 | $6 |
| Metoclopramide | 11 | $45 | $4 |
Money from drug and device companies
$1,391 in 2025
| 2025 | 12 | 89 | None | $1,391 |
| 2024 | 16 | 120 | None | $1,771 |
| 2023 | 10 | 119 | None | $1,400 |
| 2022 | 12 | 123 | None | $1,429 |
| 2021 | 13 | 105 | None | $1,144 |
| 2020 | 10 | 61 | None | $701 |
| 2019 | 12 | 148 | None | $1,134 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $581 | 30 payments
|
| Amgen | Otezla | $270 | 24 payments
|
| Ucb | Bimzelx | $216 | 14 payments
|
| GlaxoSmithKline | Benlysta | $135 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $56 | 3 payments
|
| Organon | Renflexis | $25 | 1 payment
|
See all 89 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | Saphnelo | $18 |
| Abbvie | Meals · 2025-12-17 | Rinvoq | $10 |
| GlaxoSmithKline | Meals · 2025-12-16 | Benlysta | $15 |
| Abbvie | Meals · 2025-12-15 | Rinvoq | $8 |
| Amgen | Meals · 2025-12-03 | Evenity | $11 |
| Abbvie | Meals · 2025-12-02 | Rinvoq | $15 |
| Abbvie | Meals · 2025-12-01 | Rinvoq | $7 |
| Abbvie | Meals · 2025-11-30 | Rinvoq | $9 |
| Amgen | Meals · 2025-11-26 | Otezla | $10 |
| Sandoz | Meals · 2025-11-20 | Jubbonti | $21 |
| Abbvie | Meals · 2025-11-20 | Skyrizi | $122 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-18 | Saphnelo | $23 |
| Ucb | Meals · 2025-11-13 | Bimzelx | $11 |
| Organon | Meals · 2025-11-13 | Renflexis | $25 |
| Amgen | Meals · 2025-11-12 | Tavneos | $12 |
| Abbvie | Meals · 2025-11-07 | Rinvoq | $13 |
| GlaxoSmithKline | Meals · 2025-11-04 | Benlysta | $11 |
| Abbvie | Meals · 2025-10-28 | Rinvoq | $7 |
| Amgen | Meals · 2025-10-22 | Otezla | $11 |
| Ucb | Meals · 2025-10-10 | Bimzelx | $18 |
| Abbvie | Meals · 2025-10-08 | Rinvoq | $14 |
| Abbvie | Meals · 2025-10-07 | Rinvoq | $8 |
| Abbvie | Meals · 2025-10-03 | Rinvoq | $16 |
| Amgen | Meals · 2025-09-30 | Otezla | $11 |
| Abbvie | Meals · 2025-09-24 | Skyrizi | $13 |
| Ucb | Meals · 2025-09-22 | Bimzelx | $27 |
| Amgen | Meals · 2025-09-22 | Evenity | $11 |
| GlaxoSmithKline | Meals · 2025-09-11 | Benlysta | $13 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-10 | Saphnelo | $15 |
| Ucb | Meals · 2025-08-27 | Bimzelx | $24 |
| Abbvie | Meals · 2025-08-21 | Skyrizi | $11 |
| Amgen | Meals · 2025-08-19 | Otezla | $12 |
| Abbvie | Meals · 2025-08-14 | Rinvoq | $8 |
| Amgen | Meals · 2025-08-14 | Tavneos | $7 |
| Amgen | Meals · 2025-08-13 | None | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-12 | Orencia | $16 |
| Ucb | Meals · 2025-08-08 | Bimzelx | $16 |
| GlaxoSmithKline | Meals · 2025-08-05 | Benlysta | $13 |
| Abbvie | Meals · 2025-07-30 | Skyrizi | $17 |
| Ucb | Meals · 2025-07-10 | Bimzelx | $16 |
| Amgen | Meals · 2025-07-10 | Otezla | $12 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $11 |
| Abbvie | Meals · 2025-06-25 | Rinvoq | $7 |
| Abbvie | Meals · 2025-06-25 | Rinvoq | $12 |
| Abbvie | Meals · 2025-06-19 | Rinvoq | $122 |
| Abbvie | Meals · 2025-06-19 | Rinvoq | $8 |
| Amgen | Meals · 2025-06-18 | Otezla | $11 |
| Amgen | Meals · 2025-06-17 | Evenity | $12 |
| Abbvie | Meals · 2025-06-16 | Rinvoq | $11 |
| GlaxoSmithKline | Meals · 2025-06-10 | Benlysta | $11 |
| Amgen | Meals · 2025-06-04 | Otezla | $11 |
| Abbvie | Meals · 2025-06-02 | Rinvoq | $14 |
| Ucb | Meals · 2025-05-27 | Bimzelx | $12 |
| Amgen | Meals · 2025-05-21 | Otezla | $13 |
| GlaxoSmithKline | Meals · 2025-05-15 | Benlysta | $19 |
| Abbvie | Meals · 2025-05-15 | Rinvoq | $14 |
| Amgen | Meals · 2025-05-14 | Krystexxa | $10 |
| Ucb | Meals · 2025-05-12 | Bimzelx | $17 |
| Amgen | Meals · 2025-05-07 | Otezla | $10 |
| GlaxoSmithKline | Meals · 2025-05-01 | Benlysta | $10 |
| Ucb | Meals · 2025-04-30 | Bimzelx | $14 |
| Ucb | Meals · 2025-04-16 | Bimzelx | $12 |
| GlaxoSmithKline | Meals · 2025-04-15 | Benlysta | $14 |
| Abbvie | Meals · 2025-04-10 | Skyrizi | $13 |
| Amgen | Meals · 2025-04-09 | Otezla | $10 |
| Lilly USA | Meals · 2025-03-19 | Taltz | $21 |
| Abbvie | Meals · 2025-03-18 | Skyrizi | $11 |
| Ucb | Meals · 2025-03-17 | Bimzelx | $11 |
| Ucb | Meals · 2025-03-12 | Bimzelx | $13 |
| GlaxoSmithKline | Meals · 2025-03-11 | Benlysta | $10 |
| Amgen | Meals · 2025-03-05 | Otezla | $11 |
| Abbvie | Meals · 2025-03-04 | Rinvoq | $10 |
| Amgen | Meals · 2025-02-26 | Evenity | $9 |
| ANI Pharmaceuticals | Meals · 2025-02-25 | Purified Cortrophin Gel | $22 |
| Abbvie | Meals · 2025-02-24 | Rinvoq | $9 |
| Abbvie | Meals · 2025-02-19 | Rinvoq | $14 |
| Ucb | Meals · 2025-02-12 | Cimzia | $13 |
| Amgen | Meals · 2025-02-12 | Enbrel | $12 |
| GlaxoSmithKline | Meals · 2025-02-06 | Benlysta | $9 |
| Amgen | Meals · 2025-02-05 | Tavneos | $10 |
| Abbvie | Meals · 2025-01-29 | Rinvoq | $17 |
| Amgen | Meals · 2025-01-29 | Otezla | $12 |
| Abbvie | Meals · 2025-01-22 | Rinvoq | $30 |
| GlaxoSmithKline | Meals · 2025-01-21 | Benlysta | $8 |
| Janssen Biotech | Meals · 2025-01-15 | Tremfya | $14 |
| Ucb | Meals · 2025-01-09 | Bimzelx | $11 |
| Novartis Pharmaceuticals | Meals · 2025-01-08 | Cosentyx | $14 |
| Amgen | Meals · 2025-01-08 | Enbrel | $11 |
| Amgen | Meals · 2025-01-04 | Tavneos | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,771
| Abbvie | Rinvoq | $592 | 27 payments
|
| Amgen | Enbrel | $432 | 42 payments
|
| Ucb | Cimzia | $209 | 16 payments
|
| Pfizer | Xeljanz | $130 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $73 | 4 payments
|
| Radius Health | None | $55 | 3 payments
|
| Janssen Biotech | Tremfya | $46 | 2 payments
|
| Fresenius Kabi USA | Idacio | $46 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $43 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $39 | 2 payments
|
| Hospira | Octagam Immune Globulin (Human) | $23 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $20 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $20 | 1 payment
|
| GlaxoSmithKline | Benlysta | $16 | 1 payment
|
| Genentech USA | Actemra | $15 | 1 payment
|
| Lilly USA | Omvoh | $13 | 1 payment
|
2023: $1,400
| Amgen | Enbrel | $503 | 45 payments
|
| AbbVie | Rinvoq | $385 | 35 payments
|
| Ucb | Cimzia | $165 | 15 payments
|
| Novartis Pharmaceuticals | Cosentyx | $129 | 10 payments
|
| Janssen Biotech | Tremfya | $115 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $32 | 2 payments
|
| Pfizer | Xeljanz | $29 | 2 payments
|
| Radius Health | Tymlos | $14 | 1 payment
|
| GlaxoSmithKline | Benlysta | $14 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $12 | 1 payment
|
2022: $1,429
| Abbvie | Rinvoq | $331 | 32 payments
|
| Amgen | Enbrel | $312 | 33 payments
|
| Janssen Biotech | Tremfya | $201 | 8 payments
|
| Novartis Pharmaceuticals | Cosentyx | $165 | 14 payments
|
| Pfizer | Xeljanz | $152 | 19 payments
|
| Mallinckrodt Hospital Products | Acthar | $76 | 4 payments
|
| Ucb | Cimzia | $63 | 5 payments
|
| Aurinia Pharma U.S. | Lupkynis | $57 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $41 | 3 payments
|
| Radius Health | Tymlos | $13 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $13 | 1 payment
|
| Hospira | Octagam Immune Globulin (Human) | $6 | 1 payment
|
2021: $1,144
| Amgen | Enbrel | $238 | 30 payments
|
| AbbVie | Rinvoq | $221 | 21 payments
|
| GlaxoSmithKline | Benlysta | $149 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $148 | 13 payments
|
| Novartis Pharmaceuticals | Cosentyx | $112 | 12 payments
|
| Janssen Biotech | Tremfya | $103 | 8 payments
|
| Ucb | Cimzia | $67 | 4 payments
|
| Pfizer | Xeljanz | $26 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $21 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $20 | 1 payment
|
| Radius Health | Tymlos | $15 | 1 payment
|
| Genentech USA | Rituxan | $13 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $12 | 1 payment
|
2020: $701
| Amgen | Enbrel | $235 | 28 payments
|
| GlaxoSmithKline | Benlysta | $166 | 9 payments
|
| Janssen Biotech | Simponi Aria | $110 | 11 payments
|
| AbbVie | Rinvoq | $61 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $39 | 2 payments
|
| Genzyme | Kevzara | $34 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Orencia | $25 | 2 payments
|
| Ucb | Cimzia | $14 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $11 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $6 | 1 payment
|
2019: $1,134
| Amgen | Enbrel | $324 | 49 payments
|
| Pfizer | Xeljanz | $165 | 25 payments
|
| AbbVie | Rinvoq | $128 | 18 payments
|
| Novartis Pharmaceuticals | Cosentyx | $124 | 18 payments
|
| GlaxoSmithKline | Benlysta | $115 | 13 payments
|
| Janssen Biotech | Simponi Aria | $115 | 14 payments
|
| Janssen Scientific Affairs | Stelara | $76 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $36 | 6 payments
|
| Genentech USA | Rituxan | $18 | 1 payment
|
| Merck Sharp & Dohme | Renflexis | $16 | 1 payment
|
| Ucb | Cimzia | $12 | 1 payment
|
| Fidia Pharma USA | Hymovis | $6 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1467603365
- Licence
- CA A104924California A104924: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 0A1049420
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 7880 Wren Ave Ste C131, Gilroy, CA, 95020
- NPI first listed
- 2008-10-09
- NPI last updated
- 2026-03-06
- NPI record certified
- 2026-03-06
This is when the NPI record was last certified, not a medical board exam.